Introduction
Heart failure is a clinical syndrome induced by structural and/or functional cardiac abnormalities, resulting in reduced cardiac output and/or elevated intracardiac end-diastolic pressures and causing symptoms, often accompanied by typical physical signs [1] .
The number of subjects living with heart failure has increased over recent decades because of demographic changes and, at least in part, because of the success of modern cardiology, which achieved a marked reduction in short-term mortality of several acute conditions (e.g., myocardial infarction, arrhythmia, congenital heart disease) and, by combining several drug classes and devices, improved long-term survival of patients with reduced left-ventricular ejection fraction. As a consequence, heart failure has become a major public health problem, affecting 2% of the adult population in developed countries, and the number of hospital admissions related to heart failure has tripled over the last three decades [2] .
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Acute heart failure (AHF) is defined as new-onset or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in patients aged 65 years or older. Despite major achievements in the treatment of chronic heart failure, outcomes of AHF remain poor, with high mortality and readmission rates. In this context, there is an unmet need for individualisation of AHF treatment according to the underlying pathophysiological mechanisms and for optimisation of transitions of care to, hopefully, improve patient outcome.
Congestion and the pathophysiology of acute heart failure
Heart failure was historically described with the haemodynamic model of a pump failure causing downstream hypoperfusion (forward failure) and upstream congestion (backward failure). Over recent decades, a more complex network of interactions has been added to this model for explaining the pathophysiology of heart failure. AHF may arise in patients without previous history of symptomatic heart failure (de novo AHF), mostly secondarily to an acute deterioration of the cardiac function (e.g., myocardial infarction, severe myocarditis, acute valve regurgitation) causing relevant haemodynamic alterations [3] . More frequently, AHF consists of acute decompensations of chronic heart failure (ADHF) and is caused by progressive congestion that may be precipitated by several fac-
Cardiac dysfunction induces the activation of several neuro-humoral pathways (e.g., the sympathetic nervous system, the renin-angiotensin-aldosterone system and the arginine-vasopressin system) to counter the negative haemodynamic effects of heart failure [5].
Neuro-humoral activation leads to impaired sodium excretion through the kidneys, which results in sodium and, secondarily, fluid accumulation [6] . Moreover, persistent neuro-humoral activation induces maladaptive processes resulting in detrimental ventricular remodelling and organ dysfunction.
Summary
Acute heart failure is a life-threatening condition requiring immediate diagnosis and initiation of treatment. Systemic congestion, promoted by the activation of several pathophysiological mechanisms, is the central feature of acute heart failure, and causes the typical symptoms and leads to organ dysfunction. Cardiogenic shock is the most severe form of acute heart failure and is defined by the presence of reduced cardiac output and end-organ hypoperfusion.
Decongestive therapy is the mainstay in the initial treatment of acute heart failure with congestion. Inotropes are used in cardiogenic shock patients with reduced myocardial contractility to restore end-organ perfusion.
The first 3 months after an acute heart failure episode -the vulnerable phase -are characterised by high readmission and mortality rates. Optimal patient management before and after hospital discharge is crucial to improve patient outcome. 
Diagnosis and initial treatment
The basis for the correct management of AHF patients depends on the correct diagnosis of the cardiac disease, the pathophysiology at play and comorbidities (table 1) .
The treatment consists of three steps: triage, confirmation of diagnosis and initiation of treatment, and reas- Table 1 : Principles for the correct management of patients with acute heart failure.
Diagnostic challenges Examples
Characterise the clinical syndrome Modified from Forrester et al. [18, 19] .
examination (haemodynamic and respiratory status, degree of congestion) and biomarkers (natriuretic peptides, troponin, renal function, serum lactate).
Most patients require hospital admission, about half of them to intensive or intermediate care units. Low-risk patients with a good response to initial therapy may be considered for early discharge.
Hospital discharge and the vulnerable phase
The decision about the optimal time-point for hospital discharge of hospitalised patients with AHF may be challenging. Indeed, the early post-discharge period immediately following a hospitalisation for AHF is characterised by relevant short-term mortality and frequent hospital readmissions ( fig. 3) , causing a significant burden in healthcare expenditures [30] .
The causes of this "vulnerable phase", which usually lasts 2 to 3 months, remain controversial [29] . The combination of pathophysiological derangements (e.g., persistent congestion, insufficient neuro-humoral blockade) and healthcare system problems (e.g., lack of follow-up) seems to contribute to the poor outcome.
In this context, clinicians need to balance between the risk of adverse outcome, healthcare costs and patient preferences in order to determine the optimal length of hospital stay.
Some studies suggested persistent haemodynamic congestion at hospital discharge as a critical factor in the pathophysiology underlying the high rates of death and readmission during the vulnerable phase showed an association between beta-blocker or RASI treatment at hospital discharge and a 40 to 50% relative risk reduction in 90-day mortality, and an additional 25 to 50% relative risk reduction associated with combined treatment with a beta-blocker and RASI at hospital discharge compared with a beta-blocker or RASI alone [36] . The early benefits were present with both reduced and preserved ejection fraction and persisted at 1-year follow-up. In the same study, no early benefit of early administration of MRAs was found. In patients intolerant to beta-blockers, early initiation of ivabradine might be considered to reduce readmissions during the vulnerable phase [37] . In light of these data, continuation or initiation of disease-modifying heart failure drugs (e.g., beta-blocker, RASI) before hospital discharge in all AHF patients, unless clearly contraindicated, seems reasonable.
A further critical point to consider before hospital discharge is whether the precipitating factors of AHF have been adequately treated and resolved. This includes revascularisation for myocardial ischaemia, antiarrhythmic therapy for arrhythmias, antimicrobial therapy for infection, antihypertensive therapy for hypertension and patient education for malcompliance.
Furthermore, clinicians should take care of a delayed peak in the risk of death in AHF precipitated by infec-
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Figure 3: The "vulnerable phase" after discharge for acute heart failure. The first 3 months after hospital discharge for AHF are characterised by high rate of adverse events (death and readmission). This phase is commonly defined as "vulnerable phase".
Modified from Greene et al. [29] .
tion, occurring at weeks 3 to 4 after admission ( fig. 4) [4].
Patient education, home-based collection of subjective and objective data (symptoms, body weight, blood pressure) and early contact with healthcare providers have been proposed to reduce readmission rates, but with inconsistent results. Several strategies to achieve early detection of congestion, including intrathoracic impedance monitoring and implantable haemodynamic monitoring (e.g., the CardioMEMS HF system), Key points -Acute heart failure is a life-threatening condition requiring immediate diagnosis and initiation of treatment.
Systemic congestion, promoted by the activation of several pathophysiological mechanisms, is the central feature of acute heart failure and causes the typical symptoms and leads to organ dysfunction.
Cardiogenic shock is the most severe form of acute heart failure and is defined by the presence of reduced cardiac output and end-organ hypoperfusion.
The first 3 months after an acute heart failure episode -the vulnerable phase -are characterised by high readmission and mortality rates. Optimal patient management before and after hospital discharge is crucial to improve patient outcome. Optimally, all patients with AHF should benefit from inclusion in an early, comprehensive, post-discharge care programme. If this is not feasible because of limited resources, it should be restricted to high-risk patients (e.g., elevated natriuretic peptides, abnormal systolic blood pressure, persistent hyponatraemia, recurrent readmissions) [29] . In our centre, we recommend an early visit to the general practitioner within 1 week after discharge and we schedule a visit to the HF outpatient clinic within 2 to 3 weeks after discharge.
During these early outpatient visits, assessment and optimisation of the volume status (including comparison of natriuretic peptide concentrations with predischarge values) and up-titration of disease-modifying HF treatment should be performed.
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